Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials
- 1 July 2014
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (1) , 40-45.e10
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Cause-Specific Cardiovascular Risk Associated with Nonsteroidal Anti-Inflammatory Drugs among Myocardial Infarction Patients - A Nationwide StudyPLOS ONE, 2013
- Selective cyclooxygenase-2 inhibitor cross-reactivity in aspirin-exacerbated respiratory diseaseAllergy and Asthma Proceedings, 2011
- Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory diseaseAnnals of Allergy, Asthma & Immunology, 2006
- Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory diseaseAnnals of Allergy, Asthma & Immunology, 2004
- Safety of Selective COX‐2 Inhibitors in Aspirin/Nonsteroidal Anti‐inflammatory Drug‐Intolerant Patients: Comparison of Nimesulide, Meloxicam, and RofecoxibJournal of Asthma, 2004
- The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patientsThorax, 2002
- Safety of a Cyclooxygenase-2 Inhibitor in Patients With Aspirin-Sensitive AsthmaChest, 2002
- Anaphylactoid Reaction to a Cyclooxygenase-2 Inhibitor in a Patient Who Had a Reaction to a Cyclooxygenase-1 InhibitorNew England Journal of Medicine, 2001
- ASTHMA DEATH DUE TO IBUPROFENThe Lancet, 1987
- Aspirin-sensitive rhinosinusitis asthma: A double-blind crossover study of treatment with aspirinJournal of Allergy and Clinical Immunology, 1984